<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301819</url>
  </required_header>
  <id_info>
    <org_study_id>25-5-14 V2</org_study_id>
    <nct_id>NCT02301819</nct_id>
  </id_info>
  <brief_title>ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock</brief_title>
  <acronym>ECMO-CS</acronym>
  <official_title>ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Na Homolce Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Pilsen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Na Homolce Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible patients with severe cardiogenic shock will be randomized to one of the two arms:&#xD;
      immediate ECMO therapy or early conservative therapy. In the invasive group, veno-arterial&#xD;
      ECMO will be implanted according to the local practice with flow settings to ensure&#xD;
      sufficient tissue perfusion. With the exception of ECMO implantation in the invasive group,&#xD;
      all other diagnostic and therapeutic procedures will be done according to the current&#xD;
      standard of care at the tertiary cardiovascular center, including other cardiovascular&#xD;
      interventions (i.e. percutaneous coronary intervention or cardiac surgery). Implantation of&#xD;
      other mechanical support devices including ECMO in the primary conservative group is allowed&#xD;
      in the case of shock progression with rise of serum lactate by 3 mmol/L in comparison with&#xD;
      the lowest value during the past 24 hours. Follow-up include visits at 30 days, 6 moths and&#xD;
      12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of death from any cause, resuscitated circulatory arrest, and implantation of another mechanical circulatory support device</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological outcome (according to Cerebral Performance Category scale)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Invasive</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate veno-arterial extracorporeal membrane oxygenation (ECMO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conservative</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Early conservative therapy according to standard practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Veno-arterial extracorporeal membrane oxygenation (ECMO)</intervention_name>
    <description>Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.</description>
    <arm_group_label>Invasive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early conservative therapy according to standard practice</intervention_name>
    <description>Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.</description>
    <arm_group_label>Conservative</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients must fulfil criteria for rapidly deteriorating (A) or severe (B) cardiogenic&#xD;
        shock:&#xD;
&#xD;
        A. Rapidly deteriorating cardiogenic shock is defined as progressive hemodynamic&#xD;
        instability necessitating repeated bolus administration of vasopressors to maintain mean&#xD;
        arterial pressure &gt; 50 mmHg + impaired left ventricle systolic function (Left ventricle&#xD;
        ejection fraction (LVEF) &lt; 35% or LVEF 35-55% in case of severe mitral regurgitation or&#xD;
        aortic stenosis) or&#xD;
&#xD;
        B. In severe cardiogenic shock all following criteria should be met:&#xD;
&#xD;
          1. Hemodynamic:&#xD;
&#xD;
             Cardiac Index (CI) &lt; 2.2 L/min/m2 + norepinephrine dose &gt; 0.1 μg/kg/min + dobutamin&#xD;
             dose &gt; 5 μg/kg/min or Systolic blood pressure &lt; 100 mmHg + norepinephrine dose &gt; 0.2&#xD;
             μg/kg/min + dobutamin dose &gt; 5 μg/kg/min + (LVEF &lt; 35% or LVEF 35-55% + severe mitral&#xD;
             regurgitation or aortic stenosis)&#xD;
&#xD;
          2. Metabolic:&#xD;
&#xD;
             Lactate - two consecutive values ≥ 3 mmol/L (with at least 30 min between samples),&#xD;
             with non-decreasing trend on steady doses of inotropes and/or vasopressors or SvO2 -&#xD;
             two consecutive values &lt; 50% (with at least 30 min between measurements), with&#xD;
             non-increasing trend on steady doses of inotropes and/or vasopressors&#xD;
&#xD;
          3. Hypovolemia must be excluded:&#xD;
&#xD;
        Central venous pressure &gt; 7 mmHg or pulmonary capillary wedge pressure &gt; 12 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age &lt; 18 years&#xD;
&#xD;
          2. Life expectancy lower than 1 year&#xD;
&#xD;
          3. High suspicion of pulmonary emboli or cardiac tamponade as a cause of shock&#xD;
&#xD;
          4. Significant bradycardia or tachycardia which might be responsible for hemodynamic&#xD;
             instability and not treated by pacing or cardioversion&#xD;
&#xD;
          5. Cardiac arrest survivors remaining comatose&#xD;
&#xD;
          6. Hypertrophic obstructive cardiomyopathy&#xD;
&#xD;
          7. Peripheral artery disease disabling insertion of outflow cannula to femoral artery&#xD;
&#xD;
          8. Moderate to severe aortic regurgitation&#xD;
&#xD;
          9. Aortic dissection&#xD;
&#xD;
         10. Uncontrolled bleeding or TIMI major bleeding within last 6 months&#xD;
&#xD;
         11. Known encephalopathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Petr Ostadal, MD, PhD</last_name>
    <phone>+420257272208</phone>
    <email>ostadal.petr@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <state>Select One</state>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petr Ostadal, MD, PhD</last_name>
      <phone>+420257272208</phone>
      <email>ostadal.petr@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Liberec</name>
      <address>
        <city>Liberec</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Karasek, MD</last_name>
      <phone>+420485312632</phone>
      <email>jiri.karasek@nemlib.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Pilsen</name>
      <address>
        <city>Pilsen</city>
        <zip>30460</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Rokyta, MD, PhD</last_name>
      <phone>+420 377 103 343</phone>
      <email>rokyta@fnplzen.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Belohlavek, MD, PhD</last_name>
      <phone>+420 224 96 2687</phone>
      <email>jan.belohlavek@vfn.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <reference>
    <citation>Ostadal P, Rokyta R, Kruger A, Vondrakova D, Janotka M, Smíd O, Smalcova J, Hromadka M, Linhart A, Bělohlávek J. Extra corporeal membrane oxygenation in the therapy of cardiogenic shock (ECMO-CS): rationale and design of the multicenter randomized trial. Eur J Heart Fail. 2017 May;19 Suppl 2:124-127. doi: 10.1002/ejhf.857.</citation>
    <PMID>28470919</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 23, 2014</study_first_submitted>
  <study_first_submitted_qc>November 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2014</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Na Homolce Hospital</investigator_affiliation>
    <investigator_full_name>Petr Ostadal</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

